NasdaqGS:MYGN

Stock Analysis Report

Executive Summary

Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests worldwide.


Snowflake Analysis

Mediocre balance sheet with moderate growth potential.


Similar Companies

Share Price & News

How has Myriad Genetics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MYGN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-0.4%

MYGN

-1.9%

US Biotechs

-0.09%

US Market


1 Year Return

3.1%

MYGN

11.2%

US Biotechs

23.9%

US Market

Return vs Industry: MYGN underperformed the US Biotechs industry which returned 10.9% over the past year.

Return vs Market: MYGN underperformed the US Market which returned 24.7% over the past year.


Shareholder returns

MYGNIndustryMarket
7 Day-0.4%-1.9%-0.09%
30 Day5.2%-2.6%3.1%
90 Day-11.3%14.9%10.4%
1 Year3.1%3.1%12.2%11.2%26.6%23.9%
3 Year80.8%80.8%26.5%22.4%50.9%41.2%
5 Year-24.9%-24.9%2.5%-2.3%78.1%58.5%

Price Volatility Vs. Market

How volatile is Myriad Genetics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Myriad Genetics undervalued compared to its fair value and its price relative to the market?

1.99x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: MYGN ($29.3) is trading above our estimate of fair value ($19.08)

Significantly Below Fair Value: MYGN is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: MYGN is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: MYGN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MYGN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MYGN is good value based on its PB Ratio (2x) compared to the US Biotechs industry average (3.2x).


Next Steps

Future Growth

How is Myriad Genetics forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

109.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MYGN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).

Earnings vs Market: MYGN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MYGN's is expected to become profitable in the next 3 years.

Revenue vs Market: MYGN's revenue (5% per year) is forecast to grow slower than the US market (7.5% per year).

High Growth Revenue: MYGN's revenue (5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MYGN's Return on Equity is forecast to be low in 3 years time (7.8%).


Next Steps

Past Performance

How has Myriad Genetics performed over the past 5 years?

-22.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MYGN is currently unprofitable.

Growing Profit Margin: MYGN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MYGN is unprofitable, and losses have increased over the past 5 years at a rate of -22.8% per year.

Accelerating Growth: Unable to compare MYGN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MYGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (103.3%).


Return on Equity

High ROE: MYGN has a negative Return on Equity (-1.43%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Myriad Genetics's financial position?


Financial Position Analysis

Short Term Liabilities: MYGN's short term assets ($329.5M) exceed its short term liabilities ($115.4M).

Long Term Liabilities: MYGN's short term assets ($329.5M) do not cover its long term liabilities ($401.3M).


Debt to Equity History and Analysis

Debt Level: MYGN's debt to equity ratio (20.9%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if MYGN's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: MYGN's debt is well covered by operating cash flow (40.8%).

Interest Coverage: MYGN is unprofitable, therefore interest payments are not well covered by earnings.


Balance Sheet

Inventory Level: MYGN has a low level of unsold assets or inventory.

Debt Coverage by Assets: MYGN's debt is covered by short term assets (assets are 1.5x debt).


Next Steps

Dividend

What is Myriad Genetics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.1%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate MYGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate MYGN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MYGN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MYGN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MYGN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Myriad Genetics's salary, the management and board of directors tenure and is there insider trading?

4.5yrs

Average management tenure


CEO

Mark Capone (57yo)

4.5yrs

Tenure

US$8,896,684

Compensation

Mr. Mark Christopher Capone has been the Chief Executive Officer and President at Myriad Genetics Inc. since July 1, 2015. Mr. Capone served as the President of Myriad Genetic Laboratories at Myriad Geneti ...


CEO Compensation Analysis

Compensation vs Market: Mark's total compensation ($USD8.90M) is above average for companies of similar size in the US market ($USD3.86M).

Compensation vs Earnings: Mark's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

4.5yrs

Average Tenure

52yo

Average Age

Experienced Management: MYGN's management team is considered experienced (4.5 years average tenure).


Board Age and Tenure

10.0yrs

Average Tenure

66yo

Average Age

Experienced Board: MYGN's board of directors are considered experienced (10 years average tenure).


Insider Trading

Insider Buying: MYGN insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$149,99816 Dec 19
Walter Gilbert
EntityIndividual
Role
Vice Chairman
Independent Vice Chairman
Shares5,860
Max PriceUS$25.60
BuyUS$164,22307 Nov 19
John Henderson
EntityIndividual
Role
Chairman of the Board
Independent Chairman
Shares7,000
Max PriceUS$23.46
SellUS$61,22512 Mar 19
Ralph McDade
EntityIndividual
Shares1,975
Max PriceUS$31.00

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.5%.


Management Team

  • Gary King (63yo)

    Executive Vice President of International Operations

    • Tenure: 9.5yrs
  • Jerry Lanchbury (60yo)

    Chief Scientific Officer

    • Tenure: 9.9yrs
    • Compensation: US$2.69m
  • Rishi Kacker

    Chief Technology Officer

    • Tenure: 1.5yrs
  • Scott Gleason

    Vice President of Investor Relations

    • Mark Capone (57yo)

      CEO, President & Director

      • Tenure: 4.5yrs
      • Compensation: US$8.90m
    • Ron Rogers (51yo)

      Executive Vice President of Corporate Communications

      • R. Riggsbee (48yo)

        Executive VP

        • Tenure: 5.3yrs
        • Compensation: US$3.14m
      • Alec Ford (52yo)

        President of Myriad Women’s Health

        • Tenure: 4.5yrs
        • Compensation: US$3.23m
      • Ben Jackson (40yo)

        Executive VP

        • Tenure: 0.5yrs
      • Clivetty Martinez

        Chief Compliance Officer

        • Tenure: 1yrs

      Board Members

      • Larry Best (70yo)

        Independent Director

        • Tenure: 10.3yrs
        • Compensation: US$380.49k
      • Wally Gilbert (87yo)

        Independent Vice Chairman

        • Compensation: US$369.99k
      • John Henderson (75yo)

        Independent Chairman

        • Tenure: 14.8yrs
        • Compensation: US$482.49k
      • Dennis Langer (67yo)

        Independent Director

        • Tenure: 15.7yrs
        • Compensation: US$392.49k
      • Lee Newcomer (66yo)

        Independent Director

        • Tenure: 0.3yrs
      • Colleen Reitan (59yo)

        Independent Director

        • Tenure: 0.3yrs
      • Heiner Dreismann (66yo)

        Independent Director

        • Tenure: 9.6yrs
        • Compensation: US$384.99k
      • Mark Capone (57yo)

        CEO, President & Director

        • Tenure: 4.5yrs
        • Compensation: US$8.90m
      • S. Phanstiel (61yo)

        Independent Director

        • Tenure: 10.3yrs
        • Compensation: US$399.49k

      Company Information

      Myriad Genetics, Inc.'s company bio, employee growth, exchange listings and data sources


      Key Information

      • Name: Myriad Genetics, Inc.
      • Ticker: MYGN
      • Exchange: NasdaqGS
      • Founded: 1991
      • Industry: Biotechnology
      • Sector: Pharmaceuticals & Biotech
      • Market Cap: US$2.142b
      • Shares outstanding: 74.39m
      • Website: https://myriad.com

      Number of Employees


      Location

      • Myriad Genetics, Inc.
      • 320 Wakara Way
      • Salt Lake City
      • Utah
      • 84108
      • United States

      Listings

      TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
      MYGNNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDOct 1995
      MYDDB (Deutsche Boerse AG)YesCommon StockDEEUROct 1995
      0K3WLSE (London Stock Exchange)YesCommon StockGBUSDOct 1995

      Biography

      Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests worldwide. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with deleterious or suspected deleterious germline; GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Vectra, a protein quantification test for assessing the disease activity of rheumatoid arthritis. In addition, the company offers Foresight, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; Prequel, a non-invasive prenatal screening test to screen for severe chromosomal disorders in a fetus; and Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer. Further, it provides EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice HRD, a companion diagnostic to measure three modes of homologous recombination deficiency comprising loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions in cancer cells. Additionally, the company offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. The company has collaboration with AstraZeneca for the development of an indication for BRACAnalysis CDx. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah. 


      Company Analysis and Financial Data Status

      All financial data provided by Standard & Poor's Capital IQ.
      DataLast Updated (UTC time)
      Company Analysis2020/01/23 23:48
      End of Day Share Price2020/01/23 00:00
      Earnings2019/09/30
      Annual Earnings2019/06/30


      Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.